| Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. |
| |
| 摘 要： | The epidermal growth factor receptor （EGFR） tyrosine kinase inhibitor erlotinib （also known as Tarceva or OSI-774） has shown pronfising response rates in malignant gliomas. We investigated the association between expression of EGFR and downstream signaling components and the response of malignant gliomas to erlotinib in a phase I trial of erlotinib administered either alone or with the alkylafing agent temozolomide.
|
| 关 键 词： | 表皮生长因子 受体 蛋白质激酶 B/Akt 神经胶质瘤 肿瘤反应 EGFR |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 维普 等数据库收录！ |
|
